Results post for old USC gastric cancer trial; Bristol Myers Squibb opens new Zeposia PML study

This week brought results on a long-completed trial plus two newly registered studies tied to Bristol-Myers Squibb.

• A Phase 2 study testing oxaliplatin, capecitabine, and cetuximab as first-line treatment for metastatic or unresectable gastric or gastroesophageal junction cancer has posted results. The study, sponsored by the University of Southern California with Bristol-Myers Squibb as a collaborator, is listed as completed, with results first posted on 2026-07-30.¹ The trial enrolled 75 participants and used a single-group design testing the drug combination.¹ Its primary outcome was the rate of progression-free survival at Month 4.¹
• Bristol-Myers Squibb is sponsoring a new observational study on progressive multifocal leukoencephalopathy (PML) risk in multiple sclerosis patients treated with ozanimod, sold as Zeposia. The study will evaluate the risk of PML, a rare brain infection caused by John Cunningham virus, among people with multiple sclerosis treated with ozanimod, collecting reported cases to describe patient characteristics and estimate how often PML occurs.² The study is estimated to enroll 15 participants and is currently listed as recruiting.²
• A feasibility trial testing iberdomide (CC-220) as a T cell priming agent before leukapheresis in relapsed/refractory multiple myeloma patients undergoing CAR-T therapy has been registered, with Bristol-Myers Squibb as a collaborator under lead sponsor Shambavi Richard. The trial studies whether giving iberdomide before CAR-T may improve T cell fitness, which may improve CAR-T expansion kinetics and response after infusion.³ The study is not yet recruiting and plans to enroll 22 participants.³